We are requesting continued funding of this productive training program to support predoctoral and postdoctoral fellows in the biomedical aspects of drugs of abuse. The training record of this program is outstanding, due to the quality of the trainees and preceptors and its organizational structure. A large number of individuals who received training from these preceptors have progressed to become leaders in the drug abuse field and a very impressive number have earned funding from NIDA and other sources for their substance abuse-related research. Since the submission of our last competitive application we have recruited five faculties from other institutions and many faculties from other departments in this university. Thus we are requesting support for two additional predoctoral and postdoctoral trainees our preceptors provide """"""""cutting edge"""""""" expertise in molecular, cellular, behavioral, clinical and translational aspects of this area of research. The major emphasis of this program continues to be concentrated on the pharmacology and mechanism of action of abused drugs and mechanisms of addiction. We continue to have a broad scope in our training program and expect that each preceptor will bring his or her specific expertise to the benefit of all trainees. This is accomplished through the wide variety of courses, the high level of collaboration among the mentors, the faculty serving on thesis committees and our excellent seminar series. The program has enjoyed and will continue to benefit from strong administrative support from the Department of Pharmacology and Toxicology and new up to date laboratories with modern major equipment, including confocal microscopy, mass spectrometry, and facilities for non-human primate behavioral testing. The predoctoral training program is rigorous and is characterized by two years of required course work and participation in excellent research projects. The major emphasis of all training supported by this program is on research. The faculty have earned the research support for the trainees through the significant number of grants they have generated. The research projects of the fellows in this program will continue to be directed toward elucidating the abuse potential, the cellular, molecular and behavioral mechanisms of action and pharmacological properties of drugs of abuse and addiction. Postdoctoral fellows will concentrate on research throughout their training. The faculty will provide guidance on research, teaching and the professionalism of a career in biomedical science and all aspects of becoming a productive and independent researcher. This has been a hallmark of this program and will continue to provide the atmosphere for the training of leading scholars in the drug abuse field for the future.

Public Health Relevance

The objective of this training grant is to educate the future generation of researchers who will concentrate on elucidating the actions of abused substances, understand the behavioral causes and consequences of addiction, and develop medications for the prevention and treatment of this disease. Progress in this area requires a work force of researchers with a solid knowledge of the biological processes affected by these substances and by this disease. Graduates of this program will be prepared to have an impact on the health of millions of individuals affected by this disease, their families and all society who currently spend billions of dollars a year on this medical and social problem.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
3T32DA007027-39S1
Application #
8821819
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Babecki, Beth
Project Start
1976-07-01
Project End
2016-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
39
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Donvito, Giulia; Nass, Sara R; Wilkerson, Jenny L et al. (2018) The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology 43:52-79
Wilkerson, Jenny L; Curry, Zachary A; Kinlow, Pamela D et al. (2018) Evaluation of different drug classes on transient sciatic nerve injury-depressed marble burying in mice. Pain 159:1155-1165
Hill, Rob; Disney, Alex; Conibear, Alex et al. (2018) The novel ?-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br J Pharmacol 175:2653-2661
Kyte, S Lauren; Toma, Wisam; Bagdas, Deniz et al. (2018) Nicotine Prevents and Reverses Paclitaxel-Induced Mechanical Allodynia in a Mouse Model of CIPN. J Pharmacol Exp Ther 364:110-119
Johnson, Amy R; Banks, Matthew L; Selley, Dana E et al. (2018) Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats. Neuropsychopharmacology 43:1753-1762
Hill, Rob; Dewey, William L; Kelly, Eamonn et al. (2018) Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition. Br J Pharmacol 175:2492-2503
Jacob, Joanna C; Sakakibara, Kensuke; Mischel, Ryan A et al. (2018) Ethanol Reversal of Oxycodone Tolerance in Dorsal Root Ganglia Neurons. Mol Pharmacol 93:417-426
Kyte, S Lauren; Gewirtz, David A (2018) The Influence of Nicotine on Lung Tumor Growth, Cancer Chemotherapy, and Chemotherapy-Induced Peripheral Neuropathy. J Pharmacol Exp Ther 366:303-313
Mischel, Ryan A; Dewey, William L; Akbarali, Hamid I (2018) Tolerance to Morphine-Induced Inhibition of TTX-R Sodium Channels in Dorsal Root Ganglia Neurons Is Modulated by Gut-Derived Mediators. iScience 2:193-209
Shin, Myungsun; Snyder, Helena W; Donvito, Giulia et al. (2018) Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. Mol Pharm 15:721-728

Showing the most recent 10 out of 339 publications